1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Roche Remains Positive After Tecentriq Triple-Negative Breast Cancer Data

 
• By Kevin Grogan

Clinicians and the company have heralded the IMpassion130 data presented at ESMO which showed that Roche's Tecentriq is the first immunotherapy to improve outcomes in TNBC but a slight blot on the landscape is that pretty much all of the survival benefit was seen in breast cancer patients with PD-L1 positive tumors.

two couple are showing half full and half empty side of water glass with their fingers
Roche is taking a glass-half-full attitude to IMpassion130 data • Source: Shutterstock

The excitement surrounding Roche's PD-L1 checkpoint inhibitor Tecentriq (atezolizumab) as a potential treatment for triple-negative breast cancer (TNBC) has subsided just a little despite promising data presented at ESMO from the Swiss group's closely watched IMpassion130 trial.

The late-breaking results from the study reported at the congress in Munich showed that a combination of Tecentriq and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

J&J Plans Educational Push After Darzalex Smoldering Myeloma Approval

 
• By Alaric DeArment

The FDA approved the anti-CD38 monoclonal antibody, a mainstay of multiple myeloma for a decade, for high-risk smoldering disease.

AstraZeneca Stays Coy On US Pricing Deal Impact

 
• By Andrew McConaghie

Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.

Compugen Keeps Faith In AstraZeneca TIGIT Alliance And PVRIG

 
• By Andrew McConaghie

New CEO, Eran Ophir, is banking on positive readouts from AstraZeneca and Arcus’s TIGIT programs soon validating its science as it pushes ahead with its immuno-oncology pipeline in a field littered with disappointments.

Walmsley Signs Off With GSK Growth Upgrade

 
• By Andrew McConaghie

The departing CEO announced improved full-year sales and profit forecasts before handing over to Luke Miels in January; he will then have to deliver on GSK’s upgraded forecast of £40bn revenues in 2031.

More from Therapy Areas

Lilly/Novo Get Priority Reviews For Lowering Drug Prices

 
• By Jessica Merrill

Novo Nordisk’s high-dose semaglutide for obesity and Lilly’s oral obesity candidate orforglipron were given priority review vouchers by the US Food and Drug Administration.

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Lilly, Novo Lower US Obesity Drug Prices To Secure Government Coverage

 
• By Jessica Merrill

Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.